Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2001 7
2002 11
2003 4
2004 3
2005 4
2006 1
2007 2
2017 1
2019 3
2020 3
2021 3
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

41 results
Results by year
Filters applied: . Clear all
Page 1
Cognitive impairment and decline in different MS subtypes.
Huijbregts SC, Kalkers NF, de Sonneville LM, de Groot V, Polman CH. Huijbregts SC, et al. Among authors: kalkers nf. J Neurol Sci. 2006 Jun 15;245(1-2):187-94. doi: 10.1016/j.jns.2005.07.018. Epub 2006 Apr 27. J Neurol Sci. 2006. PMID: 16643951 Review.
Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients.
van Lierop Z, Toorop AA, Coerver E, Willemse E, Strijbis E, Kalkers NF, Moraal B, Barkhof F, Teunissen CE, Killestein J, van Kempen Z. van Lierop Z, et al. Among authors: kalkers nf. Mult Scler J Exp Transl Clin. 2021 Jun 1;7(2):20552173211013831. doi: 10.1177/20552173211013831. eCollection 2021 Apr-Jun. Mult Scler J Exp Transl Clin. 2021. PMID: 34123391 Free PMC article.
Personalized extended interval dosing of natalizumab in MS: A prospective multicenter trial.
van Kempen ZLE, Hoogervorst ELJ, Wattjes MP, Kalkers NF, Mostert JP, Lissenberg-Witte BI, de Vries A, Ten Brinke A, van Oosten BW, Barkhof F, Teunissen CE, Uitdehaag BMJ, Rispens T, Killestein J. van Kempen ZLE, et al. Among authors: kalkers nf. Neurology. 2020 Aug 11;95(6):e745-e754. doi: 10.1212/WNL.0000000000009995. Epub 2020 Jul 20. Neurology. 2020. PMID: 32690785 Clinical Trial.
41 results